Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Business Wire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Contineum management to present at Stifel 2026 Healthcare Conference November 12
- ➤PIPE-791 targets idiopathic pulmonary fibrosis and chronic pain in clinical development
- ➤Johnson & Johnson is developing PIPE-307 for major depressive disorder
Expert Statements
Steve Kunszabo, Senior Director, Investor Relations & Corporate Communications at Contineum Therapeutics
“Contineum Therapeutics Senior Director, Investor Relations & Corporate Communications”
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the Stifel 2026 Healthcare Conference on Thursday, November 12th at 8:40 a.m. ET.
Get started
Create a free account to read the full story.